↓ Skip to main content

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Overview of attention for article published in Alzheimer's Research & Therapy, April 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 1,159)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
72 news outlets
blogs
1 blog
twitter
55 tweeters

Citations

dimensions_citation
122 Dimensions

Readers on

mendeley
145 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Published in
Alzheimer's Research & Therapy, April 2021
DOI 10.1186/s13195-021-00813-8
Pubmed ID
Authors

Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings

Twitter Demographics

The data shown below were collected from the profiles of 55 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 145 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 14%
Other 20 14%
Student > Bachelor 11 8%
Student > Postgraduate 8 6%
Student > Ph. D. Student 6 4%
Other 14 10%
Unknown 65 45%
Readers by discipline Count As %
Medicine and Dentistry 23 16%
Neuroscience 18 12%
Pharmacology, Toxicology and Pharmaceutical Science 9 6%
Agricultural and Biological Sciences 6 4%
Biochemistry, Genetics and Molecular Biology 6 4%
Other 13 9%
Unknown 70 48%

Attention Score in Context

This research output has an Altmetric Attention Score of 563. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2022.
All research outputs
#32,359
of 22,124,194 outputs
Outputs from Alzheimer's Research & Therapy
#3
of 1,159 outputs
Outputs of similar age
#1,242
of 335,996 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 22,124,194 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,159 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,996 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them